NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Edward M. Schaeffer(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Sandy Srinivas(Cancer Institute (WIA)), Nabil Adra(Victorian Comprehensive Cancer Centre), Yi An(Smilow Cancer Hospital), Daniel A. Barocas(Breast Cancer Research Foundation), Rhonda L. Bitting(Cancer Research Institute of the Slovak Academy of Sciences), Alan H. Bryce(Cancer Clinic), Brian F. Chapin(The University of Texas MD Anderson Cancer Center), Heather H. Cheng(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anthony V. D’Amico(Dana-Farber Brigham Cancer Center), Neil Desai(Southwestern Medical Center), Tanya B. Dorff(City Of Hope National Medical Center), James A. Eastham(Memorial Sloan Kettering Cancer Center), Thomas A. Farrington(Health Net), Xin Gao(Massachusetts General Hospital), Shilpa Gupta(University Hospitals Seidman Cancer Center), Thomas Guzzo(UPMC Hillman Cancer Center), Joseph E. Ippolito(Jewish Hospital), Michael Kuettel, Joshua M. Lang(University of Wisconsin Carbone Cancer Center), Tamara L. Lotan(Sidney Kimmel Comprehensive Cancer Center), Rana R. McKay(Moore College of Art and Design), Todd M. Morgan(Michigan Cancer Research Consortium), George J. Netto(Sylvester Comprehensive Cancer Center), Julio M. Pow‐Sang(Moffitt Cancer Center), Robert E. Reiter(Comprehensive Blood & Cancer Center), Mack Roach(UCSF Helen Diller Family Comprehensive Cancer Center), Tyler P. Robin(University of Colorado Cancer Center), Stan Rosenfeld(Office of Patient Care Services), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Daniel E. Spratt(University Hospitals Seidman Cancer Center), Benjamin A. Teply(Susan Thompson Buffett Foundation), Jonathan D. Tward(Huntsman Cancer Institute), Richard K. Valicenti(Comprehensive Blood & Cancer Center), J.K. Wong(Fox Chase Cancer Center), Ryan A. Berardi(Pancreatic Cancer Action Network), Dorothy A. Shead(Pancreatic Cancer Action Network), Deborah A. Freedman-Cass(Pancreatic Cancer Action Network)
Cited by 172
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.
Related Papers
No related papers found
Powered by citation graph analysis